Atrial fibrillation (AF) is the most common clinical arrhythmia, and an important contributor to
cardiovascular morbidity and mortality (Kannel & Benjamin, 2008). Currently available …

Atrial fibrillation (AF) is recognised as the most common sustained cardiac arrhythmia in
clinical practice. Ongoing drug development is aiming at obtaining atrial specific effects in …

Over the past several years, there has been increasing interest in understanding the basic
mechanisms underlying atrial fibrillation (AF). The rise in interest is partly related to the …

Background—Recent evidence points to functional Ca2+-dependent K+ (SK) channels in
the heart that may govern atrial fibrillation (AF) risk, but the underlying mechanisms are …

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in the clinical
setting. It is associated with substantial cardiovascular morbidity and mortality. Recent …

Atrial fibrillation (AF) is the most frequently encountered clinical arrhythmia and is associated
with increased morbidity and mortality. Ectopic activity and reentry are considered major …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is
increasing with the ageing of the population. Presently available treatment options are far …

Background: Small-conductance Ca2+-activated K+ (SK)–channel inhibitors have
antiarrhythmic effects in animal models of atrial fibrillation (AF), presenting a potential novel …

Small-conductance Ca 2+-activated potassium (SK) channels are relative newcomers within
the field of cardiac electrophysiology. In recent years, an increased focus has been given to …

Atrial fibrillation (AF) is the most common type of arrhythmia. Current pharmacological
treatment for AF is moderately effective and/or increases the risk of serious ventricular …